Aspirin resistance: an evaluation of current evidence and measurement methods
about
Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial InfarctionUnderutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.Aspirin and clopidogrel resistance: an emerging clinical entityCoronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphismCyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirinPreoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery.Aspirin: pharmacology and clinical applicationsAntiplatelet drugs: mechanisms and risks of bleeding following cardiac operationsCardiovascular pharmacology and physiology of the isoprostanes.Aspirin resistance: disparities and clinical implications.Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it.Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients.Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.Comparison of Multiplate, Platelet Function Analyzer-200, and Plateletworks in Healthy Dogs Treated with Aspirin and Clopidogrel.Establishment of reference ranges and evaluation of in vitro concentration-dependent platelet inhibition by acetylsalicylic acid for multiple electrode impedance aggregometry in healthy dogs.Platelet cyclooxygenase expression in normal dogs.
P2860
Q22306115-CB8B4A16-FB4C-4845-BAB5-34F54B4952E6Q24816911-7999600A-7D9F-4D9A-81D1-F12683980D70Q28194021-BA4B7EC7-83EC-40F8-818A-9128F301BF9EQ28210440-79D59F2D-F4F2-4813-877E-F36071441210Q28217995-A62707DC-F37C-4802-B3BA-0DD547B380ABQ33837587-7AC2E057-AA69-4FB4-8CCB-1B35B2AB49FAQ35158774-4200AA19-4D13-4683-8791-BADFCBF47FC7Q35608778-0DFFEB04-1ADE-4B66-8139-21D52CA9A94FQ35902517-15DBC34F-AA3E-4E97-9122-770FCBC7DDE4Q36591716-EDCA875F-6EBE-4508-B293-4550A8C4172EQ37227512-2FAC3C42-C011-4E1E-838F-A28C5696FD02Q38096387-38C0641C-D056-4D48-8834-15A430ED5930Q42933511-0DF8C5BB-86F9-4A4D-8C15-741302AD6EE9Q46789003-56C5EE20-C41A-4861-9246-FF2ECCC2B3F9Q48196804-ED32A87F-3742-40E0-A927-A4CDA7A3F797Q48306826-945C7890-6B7B-4F2E-B9D9-69ACB08D2AB2Q51404174-DF56FB1C-149F-4AF4-AE56-643F8D152BB0
P2860
Aspirin resistance: an evaluation of current evidence and measurement methods
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Aspirin resistance: an evaluation of current evidence and measurement methods
@ast
Aspirin resistance: an evaluation of current evidence and measurement methods
@en
Aspirin resistance: an evaluation of current evidence and measurement methods
@nl
type
label
Aspirin resistance: an evaluation of current evidence and measurement methods
@ast
Aspirin resistance: an evaluation of current evidence and measurement methods
@en
Aspirin resistance: an evaluation of current evidence and measurement methods
@nl
prefLabel
Aspirin resistance: an evaluation of current evidence and measurement methods
@ast
Aspirin resistance: an evaluation of current evidence and measurement methods
@en
Aspirin resistance: an evaluation of current evidence and measurement methods
@nl
P2860
P1433
P1476
Aspirin resistance: an evaluation of current evidence and measurement methods
@en
P2093
Christopher P Martin
Robert L Talbert
P2860
P304
P356
10.1592/PHCO.2005.25.7.942
P407
P577
2005-07-01T00:00:00Z